Dissolution test acceptance criteria are one of the points where compendial theory and laboratory practice meet — and where GMP audits most easily find observations. Understanding how the Q value works, how stages S1, S2 and S3 of the USP <711> acceptance table apply, and how the harmonised chapter relates to Ph. Eur. 2.9.3 is not an academic exercise: it is what separates a defensible result from a poorly framed OOS investigation. This guide shows how to interpret the acceptance criteria correctly, with the practical table for immediate-release products and the most common mistakes to avoid.
Dissolution test acceptance criteria: where they come from
The dissolution test measures the amount of active ingredient that goes into solution, under standardised conditions, within a defined time. The acceptance criteria are not spelled out in full in each monograph: the monograph defines the medium, the apparatus, the sampling time and the Q value, while the interpretation rules — how many units to test, when the batch passes and when testing continues with additional units — sit in the general chapters: USP <711> Dissolution for the US pharmacopeia and Ph. Eur. 2.9.3 Dissolution test for solid dosage forms for the European one.
For registered products, the acceptance criteria must also be specified and justified in the registration dossier: the compendial chapter provides the interpretation scheme, but the specification (Q value and time point) is a regulatory choice the licence holder must justify, typically following the principles of ICH Q6A and the FDA and EMA dissolution guidelines.
The Q value: what it actually represents
Q is the amount of dissolved active ingredient specified in the monograph or product specification, expressed as a percentage of the labelled content of the individual dosage unit, at a defined time point: for example "Q = 80% in 30 minutes". Two practical clarifications that make a difference in audits:
- the values Q + 5%, Q − 15% and Q − 25% in the acceptance table are absolute percentage points of labelled content, not percentages relative to Q;
- Q is not the expected batch mean: it is the threshold around which the staged scheme is built, tolerating increasing variability as the number of tested units grows.
The USP <711> acceptance table: stages S1, S2 and S3
For immediate-release (conventional-release) solid oral dosage forms, interpretation follows three successive stages. Testing stops at the first stage passed; the batch fails the test only if it does not even meet S3.
| Stage | Units tested | Acceptance criterion |
|---|---|---|
| S1 | 6 | Each unit is not less than Q + 5% |
| S2 | 6 additional (12 total) | The average of the 12 units is ≥ Q and no unit is less than Q − 15% |
| S3 | 12 additional (24 total) | The average of the 24 units is ≥ Q, not more than 2 units are less than Q − 15% and no unit is less than Q − 25% |
An example with Q = 85%: at S1 each unit must release at least 90%; at S2 the average of the 12 units must be at least 85% with no unit below 70%; at S3 the average of the 24 must remain at least 85%, with no more than 2 units below 70% and none below 60%. Moving to S2 or S3 is neither a deviation nor a retest: it is an integral part of the test design set out in the chapter. It must, however, be handled with clear procedural logic, because systematic reliance on later stages is a trend signal QA should catch.
Topics like this — compendial criteria, specifications and laboratory decisions that hold up in audits — are the daily bread of The Pragmatic GMP, our free weekly newsletter: one practical analysis a week, no filler theory. Subscribe so you don't miss the next deep dives.
USP, Ph. Eur. and JP: what "harmonised chapter" means
The dissolution test is one of the chapters subject to harmonisation between the three main pharmacopeias. The reference document is ICH Q4B Annex 7(R2), which declares the chapters Ph. Eur. 2.9.3, JP 6.10 and USP <711> usable as interchangeable in the ICH regions, but under precise conditions that companies often forget:
- interchangeability covers the basket (apparatus 1), the paddle (apparatus 2) and the flow-through cell;
- it does not apply when the dissolution medium contains enzymes, nor to dosage forms the regional compendia call gastro-resistant or delayed-release;
- it does not apply to vessels larger than 1 litre;
- medium, stirring speed, sampling times and any sinkers must still be specified and justified in the dossier.
On the European side, the EDQM also provides the non-mandatory chapter Ph. Eur. 5.17.1 (Recommendations on methods for dosage forms testing, including the section on the expression of dissolution specifications for oral dosage forms), useful when building or defending a specification not covered by a monograph.
Prolonged-release and gastro-resistant forms: different tables
The S1/S2/S3 scheme applies to immediate release. Prolonged-release and gastro-resistant forms follow dedicated acceptance tables, with multiple sampling points (and, for gastro-resistant forms, the acid stage followed by the buffer stage). Applying the immediate-release table by analogy to a modified-release form is a design error an inspector spots at first glance: the correct table must be identified in the compendial chapter and explicitly referenced in the specification and the laboratory SOP.
The most common audit mistakes
- Confusing stages with retests: S2 and S3 are not repetitions of the test but its continuation; conversely, an out-of-specification result after S3 is a full OOS and requires a formal investigation.
- Misreading the limits: treating Q − 15% as "85% of Q" instead of 15 percentage points below Q.
- Inconsistent specifications between dossier and LIMS: the Q value configured in the laboratory system must match the authorised one; discrepancies surface systematically in inspections.
- Forgetting the interchangeability conditions: declaring a "harmonised method" for a test with enzymes or non-standard vessels.
- Unanalysed trends: batches that regularly pass only at S2 deserve a trend analysis and, often, action on the process or the method.
GuideGxP recommendation
Treat dissolution acceptance criteria as a system requirement, not an analytical detail: the authorised specification, the applicable monograph, the laboratory SOP and the LIMS configuration must tell the same story, stage by stage. Define in the SOP who decides the move to S2/S3, how it is documented and when an OOS is triggered; verify at every pharmacopeial update that the chapter version referenced in your specifications is current; and prepare a written position on USP/Ph. Eur. interchangeability for multi-market products before an inspector asks for it.
To set this work up with a proven method, our guide Pharmacopoeias in GMP – Operational Guide to USP, Ph. Eur., JP and BP includes the operational tools to manage compendial divergences, reference standards and multi-region compliance, audit-ready.
